PMID- 35986570
OWN - NLM
STAT- MEDLINE
DCOM- 20230224
LR  - 20230226
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 3
DP  - 2023 Feb
TI  - Risk of cutaneous adverse events in cancer patients treated with 
      phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis 
      of randomized controlled trials.
PG  - 2227-2237
LID - 10.1002/cam4.5153 [doi]
AB  - BACKGROUND: Cutaneous adverse effects (AEs) are common following the 
      phosphoinositide-3-kinase (PI3K) inhibitors treatment. We aim to estimate the 
      incidence and risk of PI3K inhibitor-related cutaneous AEs. METHODS: The protocol 
      was submitted to the PROSPERO registry. We searched ClinicalTrials.gov and 
      international databases up to July 29, 2022. Meta-analysis was conducted by using 
      risk ratios (RRs) with 95% confidence intervals (CIs). RESULTS: Fourteen 
      randomized controlled trials (RCTs) comprising 3877 patients were analyzed in 
      this study. Compared with control arms, PI3K inhibitors showed a significant 
      increase in the risk of all-grade rash, high-grade rash, and serious rash events 
      (RR 2.29, 95% CI 1.58-3.31, p < 0.00001; RR 9.34, 95% CI 4.21-20.69, p < 0.00001; 
      RR 5.11, 95% CI 2.11-12.36, p = 0.0003). The overall incidences of all-grade rash 
      and high-grade rash were 26.2% (592/2257) and 4.4% (66/1487). Subgroup analyses 
      of all-grade rash according to cancer types and PI3K inhibitor assignations 
      identified the significant associations. PI3K inhibitors also significantly 
      increased the risk of pruritus and dry skin (RR 1.63, 95% CI 1.14-2.33, 
      p = 0.007; RR 3.34, 95% CI 2.30-4.85, p < 0.00001), with incidences of 13.4% 
      (284/2115) and 9.8% (141/1436) in the treatment group. CONCLUSION: There is a 
      significantly increased risk of some cutaneous AEs in patients using PI3K 
      inhibitors. Advance intervention is recommended in case of severe and 
      life-threatening events. Further research is required to investigate the risk 
      factors and pathogenesis.
CI  - (c) 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Wang, Yushu
AU  - Wang Y
AUID- ORCID: 0000-0002-8881-3553
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
AD  - Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital 
      Medical University. Beijing Maternal and Child Health Care Hospital, Beijing, 
      China.
FAU - Ma, Zhuo
AU  - Ma Z
AUID- ORCID: 0000-0002-3424-0139
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - An, Zhuoling
AU  - An Z
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zhang, Yi
AU  - Zhang Y
AUID- ORCID: 0000-0001-8806-847X
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
AD  - Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital 
      Medical University. Beijing Maternal and Child Health Care Hospital, Beijing, 
      China.
FAU - Feng, Xin
AU  - Feng X
AD  - Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital 
      Medical University. Beijing Maternal and Child Health Care Hospital, Beijing, 
      China.
FAU - Yu, Xiaojia
AU  - Yu X
AD  - Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20220819
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - 0 (Phosphatidylinositols)
SB  - IM
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - *Neoplasms
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - *Exanthema
MH  - Phosphatidylinositol 3-Kinases
MH  - Phosphatidylinositols
PMC - PMC9939201
OTO - NOTNLM
OT  - PI3K inhibitors
OT  - cancer
OT  - cutaneous adverse events
OT  - randomized controlled trials
OT  - rash
COIS- All authors declare that they have no conflict of interest.
EDAT- 2022/08/21 06:00
MHDA- 2023/02/25 06:00
PMCR- 2022/08/19
CRDT- 2022/08/20 02:52
PHST- 2022/08/02 00:00 [revised]
PHST- 2022/05/26 00:00 [received]
PHST- 2022/08/08 00:00 [accepted]
PHST- 2022/08/21 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2022/08/20 02:52 [entrez]
PHST- 2022/08/19 00:00 [pmc-release]
AID - CAM45153 [pii]
AID - 10.1002/cam4.5153 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Feb;12(3):2227-2237. doi: 10.1002/cam4.5153. Epub 2022 Aug 19.